What is TG Therapeutics's restricted cash?

TG Therapeutics (TGTX) reported restricted cash of $1.35M in Q1 2026.

How has TG Therapeutics's restricted cash changed year-over-year?

TG Therapeutics's restricted cash increased by 3.8% year-over-year, from $1.3M to $1.35M.

What is the long-term trend for TG Therapeutics's restricted cash?

Over 5 years (2020 to 2025), TG Therapeutics's restricted cash has grown at a 1.3% compound annual growth rate (CAGR), from $1.26M to $1.34M.

TG Therapeutics TGTX Restricted Cash

Restricted Cash at other companies

Merck & Co.MRK

$71M-31.1%

BridgeBio PharmaBBIO

——

Roivant SciencesROIV

——

Neurocrine BiosciencesNBIX

——

ViatrisVTRS

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

See full

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

See full

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Valuation

See full

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Profitability

See full

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

See full

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TG Therapeutics's restricted cash?: TG Therapeutics (TGTX) reported restricted cash of $1.35M in Q1 2026.
How has TG Therapeutics's restricted cash changed year-over-year?: TG Therapeutics's restricted cash increased by 3.8% year-over-year, from $1.3M to $1.35M.
What is the long-term trend for TG Therapeutics's restricted cash?: Over 5 years (2020 to 2025), TG Therapeutics's restricted cash has grown at a 1.3% compound annual growth rate (CAGR), from $1.26M to $1.34M.